-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On September 6, the pharmaceutical sector performed strongly.
The Shenwan Pharmaceutical Biological Industry Index rose 4.
25%, and the Shenwan Secondary Medical Service Industry Index rose 6.
43% that day
.
In terms of individual stocks, many individual stocks such as Essence Pharmaceuticals, Xinhua Medical, Asymchem, and Guangyuyuan had their daily limit
.
The core assets of the pharmaceutical sector have gradually stabilized Analysis of the daily limit of Essence Pharma on September 6 On September 6, Essence Pharma closed at the daily limit, with a closing price of 6.
68 yuan
.
The stock’s daily limit was set at 9:25, and the daily limit was not opened.
As of the closing closing, the fund was 76.
519 million yuan, accounting for 1.
38% of its circulating market value
.
It is reported that the stock is a hot stock of PD-1 inhibitor, traditional Chinese medicine, and medical concept.
On the same day, the concept of PD-1 inhibitor rose 3.
05%, the concept of traditional Chinese medicine rose 2.
72%, and the concept of medicine rose 2.
4%
.
Among them, it is estimated that the estimated value of the right to use the PDL-1 fully human monoclonal antibody technology in Greater China is US$26,220,200
.
In terms of traditional Chinese medicines, Essence Pharma owns varieties of traditional Chinese medicines such as Wang's Baochi Pills and Ji Desheng Sheyao; chemical drugs are mainly phenobarbital, phenylbutazone and fluorouracil, among which phenobarbital is mass-produced by the company; fluorouracil has passed the US FDA Certification, phenobarbital, fluorouracil, phenylbutazone and primidone have passed the European COS certification
.
According to the data, in the first half of 2021, Essence Pharma’s main revenue increased by 5.
62% year-on-year to 641 million yuan; net profit attributable to the parent increased by 1.
99% year-on-year to 106 million yuan; non-net profit increased by 3.
41% year-on-year to 103 million yuan
.
Analysis of Xinhua Medical's daily limit on September 6 On September 6, Xinhua Medical's daily limit closed with the closing price of 32.
87 yuan
.
The stock’s daily limit was set at 10:13, and the daily limit was opened once.
As of the closing closing, the fund was 37.
1118 million yuan, accounting for 0.
28% of its circulating market value.
.
It is reported that the stock is a hot stock in the concept of stomatology, private hospitals and medical equipment.
On the same day, the concept of oral cavity rose 2.
63%, the concept of private hospital rose 2.
45%, and the concept of medical equipment rose 2.
26%
.
It is understood that Xinhua Medical's medical device manufacturing segment mainly covers infection control, radiotherapy and imaging, surgical instruments and orthopedics and other products.
Among them, the company's infection control equipment varieties and output have been ranked first in China, and radiotherapy represented by medical electron linear accelerators.
Series products are at a high level
.
From the perspective of financial situation, Xinhua Medical's 2021 interim report shows that the company's main business revenue increased by 35.
8% year-on-year to 5.
46 billion yuan; net profit attributable to the parent increased by 155.
78% year-on-year to 329 million yuan; deducted non-net profit increased by 137.
46% year-on-year.
270 million yuan
.
Analysis of Asymchem's daily limit on September 6 On September 6, Asymchem's daily limit closed with a closing price of 357.
39 yuan
.
The stock has a daily limit at 11:26, and the daily limit has been opened 4 times.
As of the closing closing, the fund is 45.
4275 million yuan, accounting for 0.
05% of its circulating market value
.
It is reported that the stock is a hot stock in the concept of innovative drugs, pharmaceuticals, and chemical raw materials.
On the same day, the concept of innovative drugs rose 3.
23%, the concept of pharmaceuticals rose 2.
4%, and the concept of chemical raw materials rose 2.
39%
.
It is understood that Asymchem is one of the leading CMOs in China, engaging in customized R&D and customized production one-stop CDMO services, providing 1.
1 new drug R&D services for many domestic pharmaceutical companies; representative new drug projects include: treatment of hepatitis C, cardiovascular disease , cystic fibrosis,
etc.
From the perspective of financial situation, Asymchem's 2021 interim report shows that the company's main business revenue increased by 39.
04% year-on-year to 1.
76 billion yuan; net profit attributable to the parent increased by 36.
03% year-on-year to 429 million yuan; non-net profit increased by 27.
29% year-on-year , 353 million yuan
.
Analysis of the daily limit of Guangyuyuan on September 6 On September 6, Guangyuyuan closed the daily limit, and the closing price was 30.
24 yuan
.
The stock’s daily limit was set at 9:48, and the daily limit was not opened.
As of the closing closing, the fund was 123 million yuan, accounting for 0.
83% of its circulating market value
.
It is reported that the stock is a hot stock in liquor, traditional Chinese medicine, and medicine concepts.
On the same day, the concept of liquor rose 4.
22%, the concept of traditional Chinese medicine rose 2.
72%, and the concept of medicine rose 2.
4%
.
It is understood that Guangyuyuan is one of the oldest traditional Chinese medicine companies and drug brands in China.
It has two prescriptions, such as Guilingji and Dingkundan, and three national intangible cultural heritage Chinese medicine production processes.
In addition, its products include An Gong Approval numbers for more than 100 traditional Chinese medicines such as Niuhuang Pill and Niuhuang Qingxin Pill
.
The Shenwan Pharmaceutical Biological Industry Index rose 4.
25%, and the Shenwan Secondary Medical Service Industry Index rose 6.
43% that day
.
In terms of individual stocks, many individual stocks such as Essence Pharmaceuticals, Xinhua Medical, Asymchem, and Guangyuyuan had their daily limit
.
The core assets of the pharmaceutical sector have gradually stabilized Analysis of the daily limit of Essence Pharma on September 6 On September 6, Essence Pharma closed at the daily limit, with a closing price of 6.
68 yuan
.
The stock’s daily limit was set at 9:25, and the daily limit was not opened.
As of the closing closing, the fund was 76.
519 million yuan, accounting for 1.
38% of its circulating market value
.
It is reported that the stock is a hot stock of PD-1 inhibitor, traditional Chinese medicine, and medical concept.
On the same day, the concept of PD-1 inhibitor rose 3.
05%, the concept of traditional Chinese medicine rose 2.
72%, and the concept of medicine rose 2.
4%
.
Among them, it is estimated that the estimated value of the right to use the PDL-1 fully human monoclonal antibody technology in Greater China is US$26,220,200
.
In terms of traditional Chinese medicines, Essence Pharma owns varieties of traditional Chinese medicines such as Wang's Baochi Pills and Ji Desheng Sheyao; chemical drugs are mainly phenobarbital, phenylbutazone and fluorouracil, among which phenobarbital is mass-produced by the company; fluorouracil has passed the US FDA Certification, phenobarbital, fluorouracil, phenylbutazone and primidone have passed the European COS certification
.
According to the data, in the first half of 2021, Essence Pharma’s main revenue increased by 5.
62% year-on-year to 641 million yuan; net profit attributable to the parent increased by 1.
99% year-on-year to 106 million yuan; non-net profit increased by 3.
41% year-on-year to 103 million yuan
.
Analysis of Xinhua Medical's daily limit on September 6 On September 6, Xinhua Medical's daily limit closed with the closing price of 32.
87 yuan
.
The stock’s daily limit was set at 10:13, and the daily limit was opened once.
As of the closing closing, the fund was 37.
1118 million yuan, accounting for 0.
28% of its circulating market value.
.
It is reported that the stock is a hot stock in the concept of stomatology, private hospitals and medical equipment.
On the same day, the concept of oral cavity rose 2.
63%, the concept of private hospital rose 2.
45%, and the concept of medical equipment rose 2.
26%
.
It is understood that Xinhua Medical's medical device manufacturing segment mainly covers infection control, radiotherapy and imaging, surgical instruments and orthopedics and other products.
Among them, the company's infection control equipment varieties and output have been ranked first in China, and radiotherapy represented by medical electron linear accelerators.
Series products are at a high level
.
From the perspective of financial situation, Xinhua Medical's 2021 interim report shows that the company's main business revenue increased by 35.
8% year-on-year to 5.
46 billion yuan; net profit attributable to the parent increased by 155.
78% year-on-year to 329 million yuan; deducted non-net profit increased by 137.
46% year-on-year.
270 million yuan
.
Analysis of Asymchem's daily limit on September 6 On September 6, Asymchem's daily limit closed with a closing price of 357.
39 yuan
.
The stock has a daily limit at 11:26, and the daily limit has been opened 4 times.
As of the closing closing, the fund is 45.
4275 million yuan, accounting for 0.
05% of its circulating market value
.
It is reported that the stock is a hot stock in the concept of innovative drugs, pharmaceuticals, and chemical raw materials.
On the same day, the concept of innovative drugs rose 3.
23%, the concept of pharmaceuticals rose 2.
4%, and the concept of chemical raw materials rose 2.
39%
.
It is understood that Asymchem is one of the leading CMOs in China, engaging in customized R&D and customized production one-stop CDMO services, providing 1.
1 new drug R&D services for many domestic pharmaceutical companies; representative new drug projects include: treatment of hepatitis C, cardiovascular disease , cystic fibrosis,
etc.
From the perspective of financial situation, Asymchem's 2021 interim report shows that the company's main business revenue increased by 39.
04% year-on-year to 1.
76 billion yuan; net profit attributable to the parent increased by 36.
03% year-on-year to 429 million yuan; non-net profit increased by 27.
29% year-on-year , 353 million yuan
.
Analysis of the daily limit of Guangyuyuan on September 6 On September 6, Guangyuyuan closed the daily limit, and the closing price was 30.
24 yuan
.
The stock’s daily limit was set at 9:48, and the daily limit was not opened.
As of the closing closing, the fund was 123 million yuan, accounting for 0.
83% of its circulating market value
.
It is reported that the stock is a hot stock in liquor, traditional Chinese medicine, and medicine concepts.
On the same day, the concept of liquor rose 4.
22%, the concept of traditional Chinese medicine rose 2.
72%, and the concept of medicine rose 2.
4%
.
It is understood that Guangyuyuan is one of the oldest traditional Chinese medicine companies and drug brands in China.
It has two prescriptions, such as Guilingji and Dingkundan, and three national intangible cultural heritage Chinese medicine production processes.
In addition, its products include An Gong Approval numbers for more than 100 traditional Chinese medicines such as Niuhuang Pill and Niuhuang Qingxin Pill
.
